The cardenolide UNBS1450 is able to deactivate nuclear factor κB-mediated cytoprotective effects in human non-small cell lung cancer cells

Molecular Cancer Therapeutics

Volumn 5, Issue 2, 2006, Pages 391-399

  Mijatovic, Tatjana ^a   De Beeck, Anne Op ^a   Van Quaquebeke, Eric ^b   Dewelle, Janique ^b   Darro, Francis ^b   de Launoit, Yvan ^a   Kiss, Robert ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b Unibioscreen SA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2' OXOVORUSCHARIN; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOPLATIN; CARDENOLIDE; CARDENOLIDE DERIVATIVE; CHEMICAL COMPOUND; CISPLATIN; DIGITOXIN; DNA; DRUG METABOLITE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; OUABAIN; OXALIPLATIN; PACLITAXEL; PROTEIN SUBUNIT; SYNAPTOTAGMIN; UNBS 1244; UNBS 1450; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT DISORDER; BRAIN METASTASIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROTECTION; COLORIMETRY; CONTROLLED STUDY; DNA BINDING; DRUG CLASSIFICATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARDENOLIDES; CYTOPROTECTION; DNA; HUMANS; LUNG NEOPLASMS; MICE; NF-KAPPA B; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33644974357     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0367     Document Type: Article

References (49)

1. Rigas JR. Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 2004;9:16-23.
2. Gridelli C, Maione P, Airoma G, Rossi A. Selective cyclooxygenase-2 inhibitors and non-small-cell lung cancer. Curr Med Chem 2002;9: 1851-8.
3. Sperandio S, de Belle I, Bredesen DE. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci U S A 2000;97:14376-81.
4. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603.
5. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004;23:2950-66.
6. Lee HY, Srinivas H, Xia D, et al. Evidence that phosphatidylinositol 3-kinase-and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent pathways cooperate to maintain lung cancer cell survival. J Biol Chem 2003;278:23630-8.
7. Castillo SS, Brognard J, Petukhov PA, et al. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res 2004;64:2782-92.
8. Mayo MW, Denlinger CE, Broad RM, et al. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-κB through the Akt pathway. J Biol Chem 2003;278: 18980-9.
9. Wiener Z, Ontsouka EC, Jakob S, et al. Synergistic induction of the Fas (CD95) ligand promoter by Max and NFκB in human non-small lung cancer cells. Exp Cell Res 2004;299:227-35.
10. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
11. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004; 6:203-8.
12. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-6.
13. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309.
14. Schoner W. Endogenous cardiac glycosides, a new class of steroid hormones. Eur J Biochem 2002;269:2440-8.
15. Dmitrieva RI, Doris PA. Cardiotonic steroids: potential endogenous sodium pump ligands with diverse function. Exp Biol Med (Maywood) 2002;227:561-9.
16. Mathieu A, Remmelink M, D'Haene N, et al. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice. Cancer 2004;101:1908-18.
17. Srivastava M, Eidelman O, Zhang J, et al. Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. Proc Natl Acad Sci U S A 2004;101: 7693-8.
18. 2-terminal kinase. Cancer Res 2000;60: 3838-47.
19. Aizman O, Uhlen P, Lal M, Brismar H, Aperia A. Ouabain, a steroid hormone that signals with slow calcium oscillations. Proc Natl Acad Sci U S A 2001;98:13420-4.
20. Kaneda N, Chai H, Pezzuto JM, et al. Cytotoxic activity of cardenolides from Beaumontia brevituba stems. Planta Med 1992;58: 429-31.
21. Inada A, Nakanishi T, Konoshima T, et al. Anti-tumor promoting activities of natural products. II. Inhibitory effects of digitoxin on two-stage carcinogenesis of mouse skin tumors and mouse pulmonary tumors. Biol Pharm Bull 1993;16:930-1.
22. 2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res 2000;60: 3807-12.
23. Yeh JY, Huang WJ, Kan SF, Wang PS. Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 2003;54:112-24.
24. Stenkvist B. Cardenolides and cancer. Anticancer Drugs 2001;12: 635-38.
25. Stenkvist B. Is digitalis a therapy for breast carcinoma? Oncol Rep 1999;6:493-6.
26. Van Quaquebeke E, Simon G, Andre A, et al. Identification of a novel cardenolide (2″-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro anti-tumor activities and high in vivo tolerance: structure-activity relationship analyses. J Med Chem 2005;48:849-56.
27. +-ATPase as a signal transducer. Eur J Biochem 2002;269:2434-9.
28. +-ATPase. J Biol Chem 2004; 279:17250-9.
29. Renard P, Ernest I, Houbion A, et al. Development of a sensitive multi-well colorimetric assay for active NFκB. Nucleic Acids Res 2001;29:1-5.
30. Southern PJ, Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet 1982;1:327-41.
31. Gonen H, Bercovich B, Orian A, et al. Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of IκB-α. J Biol Chem 1999; 274:14823-30.
32. Vuillard L, Nicholson J. Hay RT. A complex containing β-TrCP recruits cdc34 to catalyse ubiquitination of IκB-α. FEBS Lett 1999;455:311-4.
33. Haura EB, Cress WD, Chellappan S, Zheng Z, Bepler G. Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies. Clin Lung Cancer 2004;6:113-22.
34. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA, Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 2006;118:209-14.
35. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
36. Akopyanz NS, Broude NE, Bekman EP, Marzen EO, Sverdlov ED. Tissue-specific expression of Na,K-ATPase β-subunit. Does β 2 expression correlate with tumorigenesis? FEBS Lett 1991;289:8-10.
37. Espinada CE, Chang JH, Twiss J, Rajasekaran SA, Rajasekaran AK. Repression of Na,K-ATPase β1-subunit by the transcription factor snail in carcinoma. Mol Biol Cell 2004;15:1364-73.
38. Sakai H, Suzuki T, Maeda M, et al. Up-regulation of Na(+),K(+)-ATPase α 3-isoform and down-regulation of the α1-isoform in human colorectal cancer. FEBS Lett 2004;563:151-4.
39. Smythe WR, Williams JP, Wheelock MJ, Johnson KR, Kaiser LR, Albelda SM. Cadherin and catenin expression in normal human bronchial epithelium and non-small cell lung cancer. Lung Cancer 1999;24:157-68.
40. Blanco D, Vicent S, Elizegi E, et al. Altered expression of adhesion molecules and epithelial-mesenchymal transition in silica-induced rat lung carcinogenesis. Lab Invest 2004;84:999-1012.
41. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
42. Mumby MC, Walter G. Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth. Physiol Rev 1993;73: 673-99.
43. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003;17:2205-32.
44. Pons S, Torres-Aleman I. Insulin-like growth factor-I stimulates dephosphorylation of IκB through the serine phosphatase calcineurin (protein phosphatase 2B). J Biol Chem 2000;275:38620-5.
45. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for sake of construction. Physiol Rev 2002;82: 373-428.
46. Nylandsted J, Gyrd-Hansen M, Danielewicz A, et al. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med 2004;200:425-435.
47. Frese S, Schaper M, Kuster JR, et al. Cell death induced by down-regulation of heat shock protein 70 in lung cancer cell lines is p53-independent and does not require DNA cleavage. J Thorac Cardiovasc Surg 2003;126:748-54.
48. Ohmori T, Nishio K, Ohta S, et al. Ouabain-resistant non-small-cell lung-cancer cell line shows collateral sensitivity to cis-diamminedichloroplatinum(II) (CDDP). Int J Cancer 1994;57:111-16.
49. Bando T, Fujimura M, Kasahara K, Matsuda T. Role of thromboxane receptor on the intracellular accumulation of cis-diamminedichloroplatinum (II) in non-small-cell but not in small-cell lung cancer cell lines. Anticancer Res 1998;18:1079-84.